Loading stock data…
AIM ImmunoTech Inc. (AIM)
$0.29-0.02 (-7.69%)
Market OpenUpdated 11:06 AM EDT
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AIM in the Healthcare sector is trading at $0.29 with a market capitalization of $11M. Wall Street consensus targets $5.25 (2 analysts), implying a +1722.3% move over the next 12 months. The stock is currently near its 52-week low of $0.21, remaining 76.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +1722.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 22) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22,000↑ | $21,000↓ | $26,000↑ | $25,000↑ | $16,000 |
| Gross Profit | $18,000↑ | -$19,000↑ | -$42,000↓ | $15,000↑ | $6,000 |
| Operating Income | -$2.23M↑ | -$2.95M↓ | -$2.45M↑ | -$2.65M↑ | -$3.62M |
| Net Income | -$3.02M↑ | -$4.17M↓ | -$3.28M↓ | -$2.79M↑ | -$3.71M |
Peer Comparison
JNJUNHPFE
Fundamentals
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampli...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-624.75%
Volume
Today's trading volume
1.32M
Recent News
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns
Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead
AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen.
Transcript: Aimia Q1 2026 Earnings Conference Call
On Wednesday, Aimia (TSX:AIM) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://app.webinar.net/EPYVWBVW2wk Summary AIM ImmunoTech Inc announced the divestiture of its specialty chemicals business, Bazzetto, and received regulatory approvals for the t
We Might See A Profit From Aimia Inc. (TSE:AIM) Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Aimia Inc.'s ( TSE:AIM...
Aimia Q4 Earnings Call Highlights
Aimia (TSE:AIM) executives told investors the company’s transformation into what it described as a “useful permanent capital vehicle” advanced in the fourth quarter of 2025, with management highlighting solid operating results in its core businesses, a higher cash balance, and progress toward a plan